Bausch Health Companies Inc. Payments to Acquire Available-for-sale Securities
Bausch Health Companies Inc. (BHC) reported Payments to Acquire Available-for-sale Securities of $11.74 million for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2011-11-04
- Bausch Health Companies Inc. payments to acquire available-for-sale securities for the quarter ending 2011-09-30 was $11.74M.
- Bausch Health Companies Inc. payments to acquire available-for-sale securities for the quarter ending 2011-06-30 was $29.33M.
- Bausch Health Companies Inc. payments to acquire available-for-sale securities for the quarter ending 2011-03-31 was $40.02M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month |
|---|---|---|---|
| 2011-09-30 | $11.74M 10-Q · filed 2011-11-04 | $41.07M derived: sum of 2 quarters · filed 2011-11-04 | $81.09M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $29.33M 10-Q · filed 2011-08-08 | $69.34M 10-Q · filed 2011-08-08 | |
| 2011-03-31 | $40.02M 10-Q · filed 2011-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |